Related Experiment Video

Updated: Aug 16, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.1K

Novel therapies in axial spondyloarthritis

Mohamad Bittar1, Philip Mease2

  • 1The University of Tennessee Health Science Center, Division of Connective Tissue Disease (Rheumatology), 956 Court Avenue, Coleman Building, Suite G326, Memphis, TN 38163, USA.

Best Practice & Research. Clinical Rheumatology
|December 24, 2022
PubMed

Insights

New treatments for axial spondyloarthritis (axSpA) are emerging due to limitations of current therapies. This review covers novel agents, future targets, and their impact on disease progression and extra-musculoskeletal symptoms.

Area of Science:

  • Rheumatology and Immunology
  • Inflammatory Disease Pathogenesis

Background:

  • Advances in understanding axial spondyloarthritis (axSpA) pathogenesis have identified key therapeutic targets.
  • Current treatments targeting interleukin-17, tumor necrosis factor (TNF), and Janus kinase (JAK) pathways show efficacy but have limitations.
  • A significant patient subset experiences treatment failure or intolerance with existing axSpA therapies.

Purpose of the Study:

  • To review recently approved and investigational agents for axSpA.
  • To explore novel therapeutic targets and mechanisms for axSpA management.
  • To discuss the role of new therapies in preventing radiographic progression and managing extra-musculoskeletal manifestations.

Main Methods:

  • Literature review of recent advancements in axSpA therapeutics.
  • Analysis of approved, clinical trial, and preclinical novel agents.
  • Discussion of therapeutic strategies for axSpA and its complications.

Main Results:

  • Several novel agents targeting distinct pathways are in development or recently approved.
  • Future therapeutic strategies aim to improve efficacy and reduce toxicity in axSpA.
  • Emerging treatments show potential in addressing radiographic progression and extra-musculoskeletal symptoms.

Conclusions:

  • The landscape of axSpA treatment is evolving with new therapeutic options.
  • Addressing unmet needs requires continued research into novel targets and mechanisms.
  • Optimizing treatment strategies is crucial for comprehensive management of axSpA patients.
Keywords:
Ankylosing spondylitisAxial spondyloarthritisBiologicsNovel therapiesSmall moleculesTreatment

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

304
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.3K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
241
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
83
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
242
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
215